Loading…
Drugs Made In America Acquisition II Corp.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in DMIIU.
▲ +2.6% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Companies of similar size in Financial Services, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AFJKAimei Health Technology Co., Ltd. | $12.10 | 172.9x | — | — | — | $38.31M |
| AEAQActivate Energy Acquisition Corp. | $10.10 | — | — | — | — | $316.25M |
| AESPAeon Acquisition I Corp. | $9.98 | — | — | — | — | $213.35M |
| APMCAmperCap Acquisition Co | $9.98 |
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.
Company description provided by Yahoo Finance.
| — |
| 255.9x |
| — |
| — |
| $199.19M |
| AXINAxiom Intelligence Acquisition Corp 1 | $10.33 | — | — | — | — | $350.53M |
| ABTCAmerican Bitcoin Corp. | $8.84 | — | 1.0x | — | -38.53% | $1.08B |